Want to take quizzes and track your credits?
Scientists from across the globe are racing to develop effective vaccines and therapeutics for coronavirus disease 2019 (COVID-19). On March 16, phase 1 clinical trials started with a vaccine candidate developed by a US-based company, supported by the National Institutes of Health and the Coalition of Epidemic Preparedness Innovations (CEPI). The next day, a Chinese biotechnology firm announced government authorization to begin clinical trials. Eight vaccine candidates are in clinical trials and more than 100 more are in preclinical development in more than 12 countries. Dozens of therapeutics are also in preclinical and clinical development.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Lawrence O. Gostin, JD, O’Neill Institute for National and Global Health Law, Georgetown University, 600 New Jersey Ave NW, Washington, DC 20001 (firstname.lastname@example.org).
Published Online: May 7, 2020. doi:10.1001/jama.2020.6641
Conflict of Interest Disclosures: Mr Bollyky reported receiving grants from Bloomberg Philanthropies. Dr Hamburg reported Global Alliance for Vaccines and Immunizations board membership; chairing the Joint Coordinating Group for the Coalition for Epidemic Preparedness Innovations; Global Health Scientific Advisory Committee for the Bill and Melinda Gates Foundation membership; and Alnylam Pharmaceuticals board of directors membership. No other disclosures were reported.
You currently have no searches saved.